ARK Innovation ETF

ARK Innovation ETF

ARKK
ARK Innovation ETFundefined flagChicago Board Options Exchange
- -
USD
- -
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

MCPAPIChat
Sector
Financial Services
Industry
Asset Management
Address
200 Central Avenue St. Petersburg FL United States of America 33701
IPO Date
Oct 31, 2014
Business
ARK Innovation ETF (ARKK) is an actively managed exchange-traded fund that seeks long-term growth of capital by investing in domestic and foreign equity securities of companies relevant to disruptive innovation. The fund offers exposure to companies across multiple themes, including artificial intelligence and robotics; DNA technologies and genomics; energy storage and electric vehicles; fintech innovation; and next-generation internet technologies, with holdings such as Tesla Inc., Roku Inc., Coinbase Global Inc., Roblox Corp., and CRISPR Therapeutics AG. ARKK operates globally, with investments spanning the United States, Europe, Asia, and other regions, and targets growth-oriented investors seeking high-conviction bets on transformative technologies. Launched in 2014 by ARK Invest and headquartered in St. Petersburg, Florida, the ETF is part of the broader ARK Invest family of thematic funds managed by Cathie Wood. In recent developments, ARKK underwent a significant portfolio rebalancing in late 2024 amid market volatility, including increased allocations to blockchain and precision therapies following the Bitcoin ETF approvals and advancements in gene-editing trials; additionally, ARK Invest announced strategic partnerships with institutional platforms for enhanced liquidity access and expanded its research team in early 2025 to bolster analytics on autonomous technology and precision medicine sectors.